Investigator's Choice of Chemotherapy

DRUG13 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Genentech, Inc., Akeso, Hoffmann-La Roche, Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

Conditions

Advanced Unresectable or Metastatic Solid MalignancyBreast Cancer MetastaticCervical CancerCervical Cancer MetastaticClassical Hodgkin LymphomaEarly Breast CancerGastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma

Phase 2

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

CompletedNCT04632992

Genentech, Inc.Advanced Unresectable or Metastatic Solid Malignancy

Start: 2021-01-13End: 2024-02-27Updated: 2025-01-08

A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations

RecruitingNCT05420779

Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.Breast Cancer Metastatic

Start: 2022-06-30End: 2026-06-30Target: 125Updated: 2024-05-08

Phase 3

Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Jiangsu HengRui Medicine Co., Ltd.Classical Hodgkin Lymphoma

Start: 2020-07-17End: 2023-12-01Target: 56Updated: 2021-02-08

A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma

RecruitingNCT05244642

AkesoHodgkin Disease Lymphoma

Start: 2022-02-15End: 2026-03-30Target: 60Updated: 2022-02-17

A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

CompletedNCT05415215

Hoffmann-La RocheEarly Breast Cancer, Inflammatory Breast Cancer, Locally Advanced Breast Cancer

Start: 2022-07-05End: 2025-11-07Updated: 2026-02-10

Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

RecruitingNCT05954442

Fudan UniversityMetastatic Breast Cancer, Mutation, Triple Negative Breast Cancer

Start: 2023-09-13End: 2026-08-31Target: 203Updated: 2024-01-16

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma

RecruitingNCT07152405

Sichuan Baili Pharmaceutical Co., Ltd.Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

Start: 2025-09-24End: 2027-06-30Target: 490Updated: 2025-11-17

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

RecruitingNCT07214779

Incyte CorporationOvarian Cancer

Start: 2025-12-09End: 2029-05-14Target: 466Updated: 2026-05-08

SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Not yet recruitingNCT07230626

CSPC Megalith Biopharmaceutical Co.,Ltd.Cervical Cancer

Start: 2025-11-20End: 2028-07-01Target: 412Updated: 2025-11-17

A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment

Not yet recruitingNCT07392060

Shanghai Jiatan Pharmatech Co., LtdCervical Cancer Metastatic

Start: 2026-02-28End: 2030-06-30Target: 440Updated: 2026-02-06

SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Not yet recruitingNCT07526792

CSPC Megalith Biopharmaceutical Co.,Ltd.Urothelial Carcinoma

Start: 2026-06-20End: 2029-12-01Target: 406Updated: 2026-04-13

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

RecruitingNCT07522073

Incyte CorporationSolid Tumors

Start: 2026-04-09End: 2029-03-19Target: 588Updated: 2026-05-08

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

RecruitingNCT07546500

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncOvarian Cancer

Start: 2026-04-17End: 2030-04-30Target: 420Updated: 2026-05-19

Related Papers

Impact of community recruitment and inclusion initiatives on enrollment in the biomarker-driven MyTACTIC trial.

2025-12-15

MyTACTIC: Activity of targeted therapy in patients (pts) with advanced solid tumors harboring specific biomarkers.

Journal of Clinical Oncology2024-06-011 citations

Improving ethnic and racial diversity within clinical trial populations through community recruitment and inclusion initiatives: Experience from MyTACTIC.

Journal of Clinical Oncology2024-05-29

MyTACTIC: Afficacy and safety of atezolizumab (atezo) + chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR).

Journal of Clinical Oncology2023-06-011 citations

Abstract CT128: A study evaluating targeted therapies in participants who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response (MyTACTIC)

Cancer Research2022-06-151 citations

A study evaluating targeted therapies in participants who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response (MyTACTIC).

Journal of Clinical Oncology2021-05-203 citations